Supplements: Difference between revisions

From WikiDemocracy
Jump to navigationJump to search
Lilly (talk | contribs)
No edit summary
No edit summary
 
(30 intermediate revisions by 2 users not shown)
Line 1: Line 1:
=====The Effects of AHCC®, a Standardized Extract of Cultured Lentinura edodes Mycelia, on Natural Killer and T Cells in Health and Disease: Reviews on Human and Animal Studies=====


[https://onlinelibrary.wiley.com/doi/10.1155/2019/3758576 by Min Sun Shin, Hong-Jai Park, Takahiro Maeda, Hiroshi Nishioka, Hajime Fujii, Insoo Kang 20/12/2019 Journal of Immunology Research]
[[Vitamin D]]


Mushrooms have been used for various health conditions for many years by traditional medicines practiced in different regions of the world although the exact effects of mushroom extracts on the immune system are not fully understood. AHCC® is a standardized extract of cultured shiitake or Lentinula edodes mycelia (ECLM) which contains a mixture of nutrients including oligosaccharides, amino acids, and minerals obtained through liquid culture. AHCC® is reported to modulate the numbers and functions of immune cells including natural killer (NK) and T cells which play important roles in host defense, suggesting the possible implication of its supplementation in defending the host against infections and malignancies via modulating the immune system. Here, we review in vivo and in vitro effects of AHCC® on NK and T cells of humans and animals in health and disease, providing a platform for the better understanding of immune-mediated mechanisms and clinical implications of AHCC®.
[[AHCC]]
=====AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections=====
 
[https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.881902/full by Judith A. Smith 21/6/22 frontiers]
[[Vitamin C]]
Objective: To determine the efficacy, safety, and durability of the use of AHCC supplementation for 6 months to support the host immune system to clear high-risk human papillomavirus (HPV) infections. The AHCC supplement is a proprietary, standardized extract of cultured lentinula edodes mycelia (AHCC®, Amino Up, Ltd., Sapporo, Japan) that has been shown to have unique immune modulatory benefits.
 
=====Lentinula edodes extract increases goblet cell number and Muc2 expression in an intestinal inflammatory model of Trichinella spiralis infection=====
[[Probiotics]]
[https://www.sciencedirect.com/science/article/pii/S0753332222003262 by Beatriz López-Cauce 6/22 ScienceDirect]
 
AHCC® is a standardized extract of cultured mushroom (Lentinula edodes) mycelia with a wide variety of therapeutic effects including anti-inflammatory, antitumor and antiviral effects. Trichinellosis, a food-borne parasitic zoonosis is caused by the nematode Trichinella spp. Infection with Trichinella is characterized by the induction of a Th1-type response at the beginning of the intestinal phase, followed by a dominant Th2-type response which is essential for parasite expulsion.
[[Nutritional Yeast]]
=====Supplementation with Active Hexose Correlated Compound Increases the Innate Immune Response of Young Mice to Primary Influenza Infection=====
 
[https://www.sciencedirect.com/science/article/pii/S002231662208539X by Ritz Barry  11/06 ScienceDirect]
[[Multivitamins]]
The emergence of H5N1 avian influenza and the threat of new or adapted viruses in bioterrorism have created an urgent interest in identifying agents to enhance the immune response to primary virus infection. Active hexose correlated compound (AHCC) is a natural mushroom extract reported to increase natural killer (NK) cell activity, survival, and bacterial clearance in young mice. However, the effects of AHCC on the response to viral infections have not been studied. In this study, young C57BL/6 mice were supplemented with 1 g AHCC/(kg body weight · d) for 1 wk prior to and throughout infection with influenza A (H1N1, PR8).
=====Personalized cancer therapy for stage IV non-small cell lung cancer: Combined use of active hexose correlated compound and genistein concentrated polysaccharide=====
[https://www.sciencedirect.com/science/article/abs/pii/S2186495012000119 by Reiki Ishizuka 7/12 ScienceDirect]
Active hexose correlated compound (AHCC) and genistein concentrated polysaccharide (GCP) were administered to patients diagnosed with stage IV non-small cell lung cancer (NSCLC) with distant metastasis (M1). AHCC and GCP were consumed orally by concurrent or sequential use. Long-term follow-up study was conducted from January 1996 to January 2012 using the individualized evidence-based medicine (EBM) approach. Forty-two cases of NSCLC were enrolled in this study.
=====The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice=====
[https://www.sciencedirect.com/science/article/abs/pii/S0041008X07001366 by Aya Hirose  15/7/07 ScienceDirect]
Cisplatin (cis-diaminedichloroplatinum (II) or CDDP) (a widely used platinum-containing anticancer drug) is nephrotoxic and has a low percentage of tolerance in patients during chemotherapy. The active hexose correlated compound (AHCC) is an extract of Basidiomycotina marketed as a supplement for cancer patients due to its nutrients and fibre content and its ability to strengthen and optimize the capacity of the immune system.
=====Genotoxicity and subchronic toxicity evaluation of Active Hexose Correlated Compound (AHCC)=====
[https://www.sciencedirect.com/science/article/abs/pii/S0273230010001881 by H. Fujii 3/11 ScienceDirect]
Active Hexose Correlated Compound (AHCC), a mushroom extract rich in α-1,4 linked glucans, is associated with immunostimulatory effects. AHCC is used in Japan as a dietary supplement to boost immune function and it also is purported to improve the symptoms of cancer and liver disease patients. A series of toxicological studies were conducted on a freeze dried preparation of AHCC (AHCC-FD) to further develop the body of evidence supporting the safety of this ingredient. AHCC-FD was not mutagenic to Salmonella typhimurium and did not exhibit clastogenicity in a mouse micronucleus assay.

Latest revision as of 16:38, 3 February 2026